The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives

The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives

Objective: Clinical efficacy of cytostatic anticancer agents can be determined with the progression-free survival (PFS) ratio. This outcome measure compares PFS achieved by a new treatment (PFS2) to the PFS of the most recent treatment on which the patient has experienced progression (PFS1). Clinica...

Full description

Bibliographic Details
Main Authors: Nienke van de Kruis, Phyllis van der Ploeg, Jody H.C. Wilting, M. Caroline Vos, Anna M.J. Thijs, Joanne de Hullu, Petronella B. Ottevanger, Christianne Lok, Jurgen M.J. Piek
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Gynecologic Oncology Reports
Subjects:
Progression-free survival ratio
Growth-modulation index
Time to progression ratio
Ovarian carcinoma
Ovarian cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578922001151

Internet

http://www.sciencedirect.com/science/article/pii/S2352578922001151

Similar Items